Sustained virological response · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower relapse rate compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Adherance to treatment · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin or participants with detectable…
Extended peginterferon plus ribavirin treatment for 72 weeks probably leads to lower adherance to treatment compared with standard peginterferon plus ribavirin treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality Deaths during and after the treatment · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes all‐cause mortality Deaths during and after the treatment compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Liver morbidity · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Serious adverse events Number of events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Quality of life SF 36 and CLDQ · people with chronic hepatitis C
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
Peginterferon alpha‐2a probably leads to higher sustained virological response Absence of viraemia 24 weeks after… compared with peginterferon alpha‐2b (moderate certainty).
1 finding from 1 review
Progression to fulminant HBV infection · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with acute HBV infection
1 finding from 1 review
Adverse events (proportion) (4 to 6 months) · people with acute HBV infection
Interferon may leads to higher adverse events (proportion) (4 to 6 months) compared with no intervention (low certainty).
1 finding from 1 review
Adverse events (number of events) · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (1 week) · people with acute HBV infection
It is very uncertain whether interferon changes health‐related quality of life (1 week) compared with no intervention (very low certainty).
1 finding from 1 review
Short‐term mortality · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found